development of anti-inflammatory active compounds
Temisis, a 100% subsidiary of Plant Advanced Technologies PAT created in December 2017 in Nancy (France), is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing a strong inflammatory component.
Temisis is committed to developing small therapeutic molecules to fulfil unmet needs in pathologies involving IL-17/23 axis of inflammation.
Contact: contact@temisis.com